The Lancet. Microbe Journal

Overview

publication venue for

Safety, recovery, and pharmacodynamics of CRISPR-Cas therapeutic SNIPR001: a phase 1, randomised, double-blind, first-in-human, dose-escalation study. 2026
Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study.. 6. 2024
Transmission of yellow fever vaccine virus through blood transfusion and organ transplantation in the USA in 2021: report of an investigation.. 4. 2023
Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study.. 4. 2023
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study.. 3. 2022
CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children, including children with HIV: a molecular diagnostics study.. 3. 2022
Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.. 3. 2022
Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials. 2026
Tackling vaccine hyporesponsiveness through global collaboration, diverse population studies, and data integration. 2025
Worldwide emergence of fluconazole-resistant Candida parapsilosis: current framework and future research roadmap. 2023

Identity

ISO Abbreviation

Lancet Microbe

Linking ISSN

2666-5247

Electronic International Standard Serial Number (EISSN)

2666-5247